Related Experiment Videos
New anticonvulsant medication uses in bipolar disorder
Po W Wang1, Terence A Ketter, Olga V Becker
1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA. wangp0@stanford.edu
CNS Spectrums
|February 24, 2004
Summary
Newer anticonvulsants offer expanded treatment options for bipolar disorder beyond traditional lithium and divalproex sodium. These agents, including lamotrigine and gabapentin, target specific symptoms and may benefit patients with treatment-refractory conditions.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Bipolar disorder treatment is evolving, with established drugs like lithium, divalproex sodium, and carbamazepine.
- Newer anticonvulsant medications have emerged, offering distinct mechanisms and potential therapeutic benefits.
Purpose of the Study:
- To review the efficacy and tolerability of newer anticonvulsant agents in bipolar disorder treatment.
- To explore the potential utility of these agents for specific symptoms and patient subgroups.
Main Methods:
- Literature review of anticonvulsants approved in the US over the last decade.
- Analysis of pharmacological actions, side effect profiles, and emerging clinical evidence for agents like gabapentin, lamotrigine, topiramate, zonisamide, oxcarbazepine, phenytoin, and levetiracetam.
Main Results:
- Gabapentin shows anxiolytic, analgesic, and hypnotic effects.
- Lamotrigine is indicated for maintenance and may help with bipolar depression and rapid cycling.
- Other agents like topiramate, zonisamide, oxcarbazepine, phenytoin, and levetiracetam show potential for specific symptoms or acute mania, though large trials are lacking for some.
Conclusions:
- Newer anticonvulsants provide diverse options for managing specific symptoms in bipolar disorder.
- While not always directly comparable to established treatments, these novel agents expand therapeutic possibilities, particularly for complex or treatment-refractory cases.